• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    ANTIMICROBIAL COMPOSITION, METHOD TO PRODUCE AN ANTIMICROBIAL COMPOSITION AND USE OF AN ANTIMICROBIAL COMPOSITION. Antimicrobial composition comprising a lactam and a hydrotope. Antimicrobial additive composition containing a lactam and a hydrotope.
    公开号:BR112015017911B1
    申请号:R112015017911-8
    申请日:2014-01-29
    公开日:2021-03-02
    发明作者:Neil James Parry；Joanne Clare O'keeffe；Christopher Francis Smith
    申请人:Unilever Ip Holdings B.V；
    IPC主号:
    专利说明:

    Field of the Invention
    [0001] The present invention relates to an improved antimicrobial composition comprising a lactam. Background of the Invention
    [0002] WO 2007/085042 and WO 2004/016588 reveal lactams for antimicrobial benefit.
    [0003] Despite the prior art, there is still a need for improved antimicrobial compositions. Summary of the Invention
    [0004] Therefore, and in a first aspect of the present invention, an antimicrobial composition comprising a lactam and a hydrotope is provided, preferably wherein the lactam is of formula (I) or (II):

    [0005] In a second aspect, an additive antimicrobial composition containing a lactam and a hydrotope is provided.
    [0006] Preferably, the antimicrobial composition and the additive composition contain 0.000001 to 50% by weight of lactam, more preferably, 0.001 to 50% by weight, even more preferably 0.01 to 5% by weight, more preferably, 0.01 to 2%.
    [0007] In a third aspect of the present invention, an antimicrobial composition comprising an additive antimicrobial composition of the second aspect is provided.
    [0008] In a fourth aspect, a method is provided for producing an antimicrobial composition comprising the steps of: (i) directly mixing a lactam with a hydrope to form an additive antimicrobial composition; (ii) mixing the antimicrobial additive composition of (i) with an aqueous vehicle.
    [0009] In a fifth aspect, a method is provided for producing an antimicrobial composition comprising the step of directly mixing a hydrotope with a lactam.
    [0010] In a sixth aspect, the present invention provides for the use of an antimicrobial composition according to the first and third aspect or an additive antimicrobial composition according to the second aspect to prevent or halt growth.
    [0011] Preferably, the antimicrobial additive composition and the method for producing such an additive composition are substantially free of additional components.
    [0012] The term "substantially free", as used in this document, should be understood as relatively little or no amount of any content. Preferably, the antimicrobial contains less than 1% by weight, more preferably, less than 0.1% by weight of additional components.
    [0013] Preferably, the aqueous vehicle is suitable for use as a vehicle for a home or personal care product. Preferred personal care products include shampoos, conditioners, deodorants, skin cleansing compositions and oral care products, such as toothpaste and mouthwashes. Preferred household care products include, for example, a hard surface cleaner or a laundry composition. Brief description of the figures
    [0014] Figure 1 shows the S. epidermidis Inhibition graph (high bars = greater efficiency; 20h max) Detailed description of the invention
    [0015] The additive antimicrobial composition according to the present invention can be used as an antimicrobial raw material, where it would be diluted in an additional composition or the composition could be a consumer product, the application of which is intended to provide effect antimicrobial to a substrate or even as a preservative when added to a consumer composition.
    [0016] Preferably, the lactam is of formula (I) or (II):

    [0017] Preferably, the lactam is of formula (I) or (II), in which: - R1 and R2 are independently selected from hydrogen, halogen, alkyl, cycloalkyl, alkoxy, oxoalkyl, alkenyl, heterocyclyl, heteroaryl, aryl and aralalkyl ; and - R3 is selected from hydrogen, hydroxyl, alkyl, cycloalkyl, alkoxy, oxoalkyl, alkenyl, heterocyclyl, heteroaryl, cycloalkyl, aryl, aralalkyl and -C (O) CR6 = CH2; - R4 and R5 are independently selected from hydrogen, aryl, heterocyclyl, heteroaryl, and arylalkyl; e - R6 is selected from hydrogen and methyl; and - R7 is selected from hydrogen and -C (O) CR6 = CH2; and
    [0018] Preferably, at least one of R4 and R5 is hydrogen; and
    [0019] Preferably, at least one of R1 and R2 is selected from heterocyclyl, heteroaryl, aryl and arylalkyl; and
    [0020] Preferably, R1 is hydrogen. Preferably, R3 is hydrogen. Preferably, R4 is hydrogen. Preferably, R5 is hydrogen. Preferably, R6 is hydrogen; and
    [0021] Preferably, R2 is aryl or aralkalkyl. More preferably, R2 comprises a halogen-substituted phenyl group.
    [0022] Preferably, the hydrope is selected from monopropylene glycol, dimethyl sulfoxide, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene derivatives of castor oil and ethanol.
    [0023] Preferably, the hydrope is present in from 0.001 to 25% by weight of the composition.
    [0024] Preferred lactams include: - 5-methylene-4- (4'-bromophenyl) -dihydropyrrol-2-one (Ref. 295) - 5-methylene-4- (2'-fluorphenyl) -dihydropyrrol-2-one (Ref. 310) - 5-methylene-4-phenyl-1H-pyrrole-2 (5H) -one (Ref. Unsubstituted) - methyl-2- (3- (4-fluorophenyl) -2-methylene-5- oxo-2,5-dihydro-1H-pyrrol-1-yl) (Ref. 309) - 3-Bromo-4-hexyl-5- (bromomethylene) -2 (5H) -furanone (Ref. 113) - 4- (4-Trifluormethyl) phenyl) -2 (5H) -furanone (Ref. 265) - 5-Hydroxy-5-methyl-4- (2'-fluorophenyl) -dihydropyrrol-2-one (Ref. 313) - 5- (Thiophenyl-3-methylene) furan- (2H) -one (Ref. 350)
    [0025] The most preferred lactams are: - 5-methylene-4- (4'-bromophenyl) -dihydropyrrol-2-one (Ref. 295) - 5-methylene-4- (2'-fluorphenyl) -dihydropyrrol-2 -one (Ref. 310) - 5-methylene-4-phenyl-1H-pyrrole-2 (5H) -one (Ref. unsubstituted) - methyl-2- (3- (4-fluorophenyl) -2-methylene- 5-oxo-2,5-dihydro-1H-pyrrol-1-yl) (Ref. 309)
    [0026] Preferably, the hydrope is selected from monopropylene glycol, dimethyl sulfoxide, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene derivatives of castor oil and ethanol.
    [0027] Preferably, the polyoxyethylene sorbitan fatty ester is a monoester selected from monolaurate, monopalmitate, monostearate and monooleate.
    [0028] Preferably, the polyoxyethylene sorbitan fatty ester comprises from 5 to 80 oxyethylene units, more preferably, from 10 to 45 and most preferably, 20.
    [0029] Examples include Polysorbates 20, 40, 60 and 80.
    The most preferred polyoxyethylene sorbitan fatty ester is Polysorbate 20.
    [0031] Preferably, the polyoxyethylene derivative of castor oil comprises from 10 to 50 oxyethylene units, more preferably, from 30 to 45 and more preferably, 40. Examples include hydrogenated castor oils PEG-20, 40 and 60.
    [0032] The most preferred polyoxyethylene derivative of castor oil is hydrogenated castor oil PEG-40.
    [0033] Preferably, the composition is a home care or personal care product.
    [0034] Preferred personal care products include shampoos, conditioners, deodorants, skin cleansing compositions and oral care products, such as toothpaste and mouthwashes. Preferred home care products include a hard surface cleaner or a laundry composition. Lactamas
    [0035] Suitable lactams are disclosed in WO 2007/085042 and WO 2004/016588, the contents of which, in specific relation to the manufacture of lactams and WO 2007/085042, the manufacture of acrylate polymers with certain lactams associated with themselves, is incorporated into this document by reference.
    [0036] For example:

    EXAMPLES Example 1
    [0037] The following data illustrates the antimicrobial efficacy of a laundry washing composition (hereinafter referred to as the 'base composition') comprising a lactam (Ref. 295 and Ref. Unsubstituted) and a hydrotope (monopropylene glycol), but only when the hydrotope is mixed with lactam before adding to the rest of the composition. The test samples were as follows: - Lactam and hydrotope only - B lactam added directly to the base formulation (containing MPG) - no premix before addition - C lactam premixed with hydrotope and then added to the base formulation - D only hydrotope added to the base formulation
    [0038] Base Formulation


    [0039] Test samples were diluted in sterile water to reach a level of 11.5 ppm lactam. The diluted solution (80μl) was added to a suspension of S. epidermidis (20μl) of bacteria at a concentration of 8 logs in a microplate. Growth media (100μl of tryptone soy broth) were added to each well of the microplate and incubated for 20 hours. Bacterial respiration was measured every 30 minutes and the results were: A - lactam + hydrotope only (surviving bacteria respiration detected ~ 4-5h) B - lactam added directly to the base formulation (which contains MPG) - no premix before addition (breathing of surviving bacteria detected 4-5h). C - lactam premixed with hydrotope and then added to the base formulation (surviving bacteria breath not detected - 20h is the maximum detection time) D - hydrotope added to the base formulation (breath of surviving bacteria detected 3-4h) .
    [0040] The results are shown in Figure 1. Example 2
    [0041] The following example illustrates the wide application of the present invention in the scope of lactams.
    [0042] The example below is data obtained by pre-mixing lactams with hydrotope before adding to the rest of the composition, and diluting at 11.5 ppm and 0.575 ppm in sterile water to evaluate the effectiveness against suspension of S. epidermidis. Diluted solution (80μl) was added to a suspension of S. epidermidis (20μl) of bacteria in a concentration of 8 logs in a microplate. Growth media (100μl of tryptone soy broth) were added to each well of the microplate and incubated for 20 hours. Bacterial respiration was measured every 30 minutes. Data from the test samples were then compared with suspensions of untreated cells (sterile water added instead of test samples) and the percentage of inhibition was calculated.
    Example 3
    [0043] The purpose of this example was to investigate methods of achieving solubility of 5-methylene-4-phenyl-1-H-pyrrole-2 (5H) -one (Ref. Unsubstituted) in the following base formulation described above.
    [0044] An ultrasonic mixer was used to obtain or determine the solubility.
    [0045] We use a UP200S sonic tip (200W) from Hielscher in batches of 5-20ml. We Sonic for up to 60 minutes.



    [0046] Polysorbates and pegylated castor oil were considered adequate enough to continue the experimentation. Additional evaluations with each candidate solubilizer
    [0047] Next, we tested the candidate solubilizers with 1% lactam, both with 72 hours of high-speed magnetic stirring (with a constant temperature of ~ 50 ° C in the case of solubilizers that solidify alone at room temperature) and also 20 minutes of Sonication. Preparation of Lactama Solutions
    [0048] In each case, we incorporate the lactam powder into the solubilizers (at the levels indicated in the table below) using high speed agitation to prevent lumps from forming. Once the powder was added, the mixing method described (continuous high speed stirring or ultrasonic mixing) was initiated. In the cases of Sorbitano Oleate and Polysorbate-60, we apply initial heating to approx. 50 ° C to ensure that the solubilizers are completely liquid before starting lactam addition. Both of these materials do not flow at room temperature. Hydrogenated castor oil PEG-40 required initial heating to ~ 35 ° C to ensure complete fluidity before starting. Incorporation of Lactama Solutions in the Base
    [0049] The base sample provided had a 'gap' of 5% purposely left as space for the lactam solution to be added. We made sure that the lactam solutions were completely uniform through constant mechanical agitation (to avoid the deposition of any unsolubilized lactam material) and added them to the base using low speed agitation to incorporate them without generating aeration. Stability Testing
    [0050] We conducted stability tests on all test variants that looked positive (that is, a reasonable proportion of the lactam was solubilized). We prepare samples of the test variants in transparent plastic bottles and place them under different temperature conditions: • Room temperature. • 40 ° C. • 50 ° C. • Refrigerator. • Hard light ('workshop' window).
    [0051] The objective was to observe any difference in color, viscosity, solubility or general physical stability. The samples were evaluated every day and compared with the room temperature sample to observe any changes. All samples were allowed to equilibrate to room temperature before being evaluated.








    Observation and Formulation Rules Temperature and Color Change
    [0052] One of our first observations was the color change, which was visible in all successful (or partially successful) samples. We saw the development of a slight amber color to the solution when some lactam was beginning to become solubilized. This color change progressed rapidly when the samples exceeded 50 ° C, resulting in a dark brown color. When the temperature reached 65 ° C, the dark brown color was practically opaque *.
    [0053] * This temperature level has only been tested for the Polysorbate-20 and Hydrogenated Castor Oil PEG-40 variants.
    [0054] From observations throughout the project, we concluded that ~ 50 ° C was the ideal temperature to solubilize the lactam. Mixing Conditions
    [0055] Very long periods of mechanical agitation (48-72 hours) resulted in improvements in solubilization compared to shorter periods; however, we conclude that this mixing duration is not sufficient for complete solubilization. The ultrasonic mixing proved to be much more successful, and we concluded that it would be necessary for effective solubilization, certainly with the final candidates Polysorbate-20 and Hydrogenated Castor Oil PEG-40.
    [0056] From all the tests conducted, we believe that with the correct ultrasonic mixing conditions (energy in relation to batch size in relation to the maximum temperature of 50 ° C controlled), efficient solubilization could be achieved.
    权利要求:
    Claims (11)
    [0001]
    1. Antimicrobial composition, characterized by comprising a lactam and a hydrotope, where (1) the lactam is of formula (I):
    [0002]
    2. Antimicrobial composition according to claim 1, characterized by the lactam being selected from the group consisting of: 5-methylene-4- (4'-bromophenyl) -dihydropyrrol-2-one, 5-methylene-4- (2 ' - fluorophenyl) -dihydropyrrol-2-one, and mixtures thereof.
    [0003]
    Antimicrobial composition according to any one of claims 1 to 2, characterized in that the hydrope is present from 0.001 to 5% by weight of the composition.
    [0004]
    Antimicrobial composition according to any one of claims 1 to 3, characterized in that the lactam is present from 0.001 to 50% by weight of the composition, preferably 0.01 to 5% by weight of the composition, more preferably 0.01 to 2%.
    [0005]
    Antimicrobial composition according to any one of claims 1 to 4, characterized in that the hydrope is a polyoxyethylene derivative of castor oil comprising from 10 to 50, preferably from 30 to 45 and more preferably, 40 units of oxyethylene.
    [0006]
    Antimicrobial composition according to any one of claims 1 to 4, characterized in that the hydrope is a polyoxyethylene sorbitan fatty ester comprising from 5 to 80 oxyethylene units, more preferably, from 10 to 45 and more preferably, 20.
    [0007]
    7. Use of the antimicrobial composition according to any one of claims 1 to 6, characterized in that it is used in a composition for home or personal care.
    [0008]
    8. Use of the antimicrobial composition according to claim 7, characterized in that the composition for home or personal care is selected from the group consisting of shampoo, conditioner, deodorant, skin cleansing composition, and antiperspirant.
    [0009]
    9. Method for producing an antimicrobial composition, as defined in any one of the preceding claims, characterized in that it comprises the step of directly mixing a hydrotope with a lactam, as defined in claim 1.
    [0010]
    A method for producing an antimicrobial composition according to claim 9, characterized in that it comprises the steps of: (i) directly mixing a hydrotope with a lactam, as defined in claim 1, to form an antimicrobial composition; and (ii) mixing the antimicrobial composition of step (i) with an aqueous vehicle.
    [0011]
    11. Non-therapeutic use of an antimicrobial composition, as defined in any one of claims 1 to 6, characterized in that it is to prevent or interrupt microbial growth in a composition of washing clothes, cleaning of rigid surfaces and cleaning of bathrooms.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112015017911B1|2021-03-02|antimicrobial composition, method for producing an antimicrobial composition and use of an antimicrobial composition
    JP6086910B2|2017-03-01|Use of isosorbide monoester as a thickener
    BR102016023036B1|2021-06-29|RETICULATED POLYGLYCEROL ESTERS
    CN1272783A|2000-11-08|Dermatological compositions
    JP2014525972A|2014-10-02|Use of isosorbide diester as thickener
    BR112018002983B1|2021-06-29|COMPOSITION INCLUDING A LACTAM AND AN ALCOHOL
    Macário et al.2018|The antagonist and synergist potential of cholinium-based deep eutectic solvents
    CN107519028A|2017-12-29|A kind of sunscreen composition containing novel inorganic sun-screening agent
    BR112018003182B1|2021-07-13|COMPOSITION INCLUDING LACTAM AND NON-IONIC SURFACE ACTIVE
    JP2684615B2|1997-12-03|Skin cosmetics
    TW201919591A|2019-06-01|Alopecia relaxation composition including an apigenin with improved solubility
    CN109288729A|2019-02-01|A kind of multiple-effect restorative facial cream for baby
    JP2010120879A|2010-06-03|Skin care preparation for external use and manufacturing method of the same
    JP2010275231A|2010-12-09|Hair cosmetic
    JP2013199498A|2013-10-03|Skin care preparation and manufacturing method of the same
    JP6395200B2|2018-09-26|Silicon-containing compound aqueous solution and antibacterial / antiviral agent containing the aqueous solution
    CN106572958A|2017-04-19|Oil-in-water type emulsion cosmetic
    JP2012158570A|2012-08-23|Emulsion
    JP5948153B2|2016-07-06|Cosmetics-containing articles
    Al-Tameemi2021|The Use of Deep Eutectic System for Quetiapine Fumarates Release
    KR20180134572A|2018-12-19|Organic And Inorganic Complex Using Titanium Dioxide Inorganic Powder, Cosmetic Composition Including The Same, And Method Preparing Thereof
    JP6235225B2|2017-11-22|Manufacturing method of cosmetics
    WO2012035855A1|2012-03-22|Collagen production promoter, hyaluronic acid production promoter and wrinkle ameliorating agent
    CN109172444A|2019-01-11|A kind of leave hand cleanser and preparation method thereof
    JP2015059085A|2015-03-30|Skin-whitening agent
    同族专利:
    公开号 | 公开日
    CN105050393A|2015-11-11|
    ZA201505403B|2019-01-30|
    AU2014211458B2|2016-08-11|
    BR112015017911A2|2017-07-11|
    WO2014118240A1|2014-08-07|
    DE212014000038U1|2015-09-21|
    CN105050393B|2018-07-03|
    EP2950645B1|2020-10-21|
    US9930888B2|2018-04-03|
    EP2950645A1|2015-12-09|
    US20150351393A1|2015-12-10|
    AU2014211458A1|2015-08-13|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE3910921C1|1989-04-05|1990-05-17|Bayer Ag, 5090 Leverkusen, De|
    US5266590A|1989-12-11|1993-11-30|Isp Investments Inc.|Cold stabilization of aqueous microemulsions of a water-insoluble agriculturally active compound|
    AU656568B2|1991-02-12|1995-02-09|Isp Investments Inc.|Stabilization of microemulsions containing an agiculturally active ingredient using a lactam|
    EP0946089A1|1996-12-20|1999-10-06|Basf Corporation|Plant growth regulators in pyrrolidone solvents|
    AT248773T|1997-10-14|2003-09-15|Isp Investments Inc|STABILIZED CONCENTRATES OF WATER-UNSTABLE AZA COMPOUNDS AND WATER / OIL MINI EMULSIONS THEREOF|
    AU2002950862A0|2002-08-19|2002-09-12|Biosignal Pty Ltd|Furanone derivatives and methods of making same|
    KR101347278B1|2006-01-24|2014-01-03|바이오시그널 리미티드|Novel lactams|
    WO2008052031A2|2006-10-24|2008-05-02|Alcon Research, Ltd.|2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions|
    KR20100068265A|2007-08-29|2010-06-22|에이전시 포 사이언스, 테크놀로지 앤드 리서치|Sugar-based surfactant microemulsions containing essential oils for cosmetic and pharmaceutical use|
    CN102257117B|2008-12-18|2014-12-03|荷兰联合利华有限公司|Laundry detergent composition|
    IT1400721B1|2010-07-07|2013-06-28|Baldacci Lab Spa|COMPOSITIONS BASED ON PYRROLIDONCARBOSSIC ACID AND METAL SALTS.|WO2017029093A1|2015-08-20|2017-02-23|Unilever Plc|Improved lactam solubility|
    BR112018002983B1|2015-08-20|2021-06-29|Unilever Ip Holdings B.V.|COMPOSITION INCLUDING A LACTAM AND AN ALCOHOL|
    US10561142B2|2015-08-20|2020-02-18|Conopco, Inc.|Dispersed lactams|
    ES2758300T3|2015-08-20|2020-05-05|Unilever Nv|Improved lactam solubility|
    CN107920976A|2015-08-20|2018-04-17|荷兰联合利华有限公司|Improved lactams solubility|
    EP3337453A1|2015-08-20|2018-06-27|Unilever PLC|Lactam compositions|
    US20180228151A1|2015-08-20|2018-08-16|Conopco, Inc., a/b/a UNILEVER|Encapsulated lactams|
    CN107848968B|2015-08-20|2021-06-18|荷兰联合利华有限公司|Process for preparing lactams from glyoxylic acid|
    CN109475526A|2016-07-21|2019-03-15|荷兰联合利华有限公司|For treating the lactams of respiratory tract infection|
    CN109475527A|2016-07-21|2019-03-15|荷兰联合利华有限公司|For treating the lactams of skin injury|
    WO2018015280A1|2016-07-21|2018-01-25|Unilever Plc|4--5-methylene-pyrrol-2-one and 5-methylene-4-pyrrol-2-one for use in the treatment of gram negative bacterial infections|
    CN109922659A|2016-11-17|2019-06-21|荷兰联合利华有限公司|Lactam composition|
    US20200062706A1|2016-11-17|2020-02-27|Conopco, Inc., D/B/A Unilever|Lactam compostions|
    US20210332526A1|2018-09-14|2021-10-28|Conopco, Inc., D/B/A Unilever|Lactam coated textile|
    EP3963017A2|2019-05-01|2022-03-09|Novochem Green Additives B.V.|Eutectic composition|
    法律状态:
    2018-02-27| B06F| Objections, documents and/or translations needed after an examination request according art. 34 industrial property law|
    2019-07-09| B07A| Technical examination (opinion): publication of technical examination (opinion)|
    2020-07-14| B06A| Notification to applicant to reply to the report for non-patentability or inadequacy of the application according art. 36 industrial patent law|
    2020-12-01| B09A| Decision: intention to grant|
    2021-02-09| B25A| Requested transfer of rights approved|Owner name: UNILEVER IP HOLDINGS B.V. (PB) |
    2021-03-02| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/01/2014, OBSERVADAS AS CONDICOES LEGAIS. |
    优先权:
    申请号 | 申请日 | 专利标题
    EP13153600|2013-02-01|
    EP13153600.5|2013-02-01|
    PCT/EP2014/051731|WO2014118240A1|2013-02-01|2014-01-29|Antimicrobial composition comprising a lactam and a hydrotrope|
    [返回顶部]